First Report Customer Care 
All time: 4.6

Latest / Last 30 Days: 5.0

527 Reviews

Credit Rating - IMMUNOVA THERAPEUTICS LIMITED

ANALYSIS
Credit Risk Update: ACCOUNTS DUE FLAG: IMMUNOVA THERAPEUTICS LIMITED, 7TH FLOOR, CAPELLA, 60 YORK STREET, GLASGOW, G2 8JX. The legal status is a Private Limited Company and the current status at the registry of companies is Active. The last filed accounts are dated 31 December 2022. The company was incorporated on 21 September 2016.

The accounts next due date is 30 September 2024. There are no mortgages.

The above was based on public record information as at 12 October 2024 and may not reflect the current status. Please access the current report to ascertain the current status and credit rating.
SUMMARY
Registered Number: SC545846
Date Incorporated: 21 September 2016
Date Latest Accounts: 31 December 2022
BUSINESS INFORMATION
Legal Form: Private Limited Company
Previous Names: MODULATE THERAPEUTICS LIMITED
Registered Number: SC545846
Annual Return: Unknown
Registered Office: 7TH FLOOR, CAPELLA, 60 YORK STREET, GLASGOW, G2 8JX
SIC Code and Operations: 74909
SECURED CREDITORS
Number of Mortgages 0
Satisfied Mortgages 0
Part Satisfied Mortgages 0
Unsatisfied Mortgages 0
CREDIT RISK RATING
This is the credit risk assessment used by one of the top UK credit reference agencies.
Risk Score (1-100):

IMMUNOVA THERAPEUTICS LIMITED

Click Here

to view this information

Risk Assessment:
Credit Rating:



First Report Score: (0-10):

Financial Status Guide:
10  trafficlight Very Strong
9   Strong
8 Very Good
7 Good
6 Above Average
5 Average
4 Below Average
3 Poor
2 Weak
1 Very Weak
0 Critical
Report Created On 22 October 2024 Copyright © 2024 First Report Ltd


Recent Searches

Reg No. Reg Name Status
14763384 IMMUNOVAC LIMITED Active - Proposal to Strike off
09599400 IMMUNOVADIS HOLDINGS LTD Active
09601031 IMMUNOVADIS LTD Active
11460737 IMMUNOVANT SCIENCES HOLDINGS LIMITED Active
06622266 IMMUNOX THERAPEUTICS LIMITED Dissolved

In using this service you agree to the Terms and Conditions

© 2024 First Report Ltd